CL2023001750A1 - Compuestos útiles para inhibir canales de sodio activados por voltaje de nav1.8 y tratar enfermedades - Google Patents
Compuestos útiles para inhibir canales de sodio activados por voltaje de nav1.8 y tratar enfermedadesInfo
- Publication number
- CL2023001750A1 CL2023001750A1 CL2023001750A CL2023001750A CL2023001750A1 CL 2023001750 A1 CL2023001750 A1 CL 2023001750A1 CL 2023001750 A CL2023001750 A CL 2023001750A CL 2023001750 A CL2023001750 A CL 2023001750A CL 2023001750 A1 CL2023001750 A1 CL 2023001750A1
- Authority
- CL
- Chile
- Prior art keywords
- voltage
- sodium channels
- inhibiting
- gated sodium
- treating diseases
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 6
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 4
- 108010056565 NAV1.8 Voltage-Gated Sodium Channel Proteins 0.000 title abstract 2
- 102000004194 NAV1.8 Voltage-Gated Sodium Channel Human genes 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 208000002193 Pain Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 101000654356 Homo sapiens Sodium channel protein type 10 subunit alpha Proteins 0.000 abstract 1
- 102100031374 Sodium channel protein type 10 subunit alpha Human genes 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063127341P | 2020-12-18 | 2020-12-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2023001750A1 true CL2023001750A1 (es) | 2024-01-19 |
Family
ID=79025144
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2023001750A CL2023001750A1 (es) | 2020-12-18 | 2023-06-15 | Compuestos útiles para inhibir canales de sodio activados por voltaje de nav1.8 y tratar enfermedades |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP4262978A1 (zh) |
JP (1) | JP2024502231A (zh) |
KR (1) | KR20230121827A (zh) |
CN (1) | CN116710463A (zh) |
AU (1) | AU2021403606A1 (zh) |
CA (1) | CA3202328A1 (zh) |
CL (1) | CL2023001750A1 (zh) |
CO (1) | CO2023008049A2 (zh) |
IL (1) | IL303795A (zh) |
MX (1) | MX2023007244A (zh) |
WO (1) | WO2022129283A1 (zh) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ760006A (en) * | 2013-12-13 | 2022-07-29 | Vertex Pharma | Prodrugs of pyridone amides useful as modulators of sodium channels |
-
2021
- 2021-12-16 KR KR1020237023878A patent/KR20230121827A/ko unknown
- 2021-12-16 JP JP2023536951A patent/JP2024502231A/ja active Pending
- 2021-12-16 WO PCT/EP2021/086101 patent/WO2022129283A1/en active Application Filing
- 2021-12-16 IL IL303795A patent/IL303795A/en unknown
- 2021-12-16 CN CN202180085151.XA patent/CN116710463A/zh active Pending
- 2021-12-16 EP EP21831047.2A patent/EP4262978A1/en active Pending
- 2021-12-16 CA CA3202328A patent/CA3202328A1/en active Pending
- 2021-12-16 AU AU2021403606A patent/AU2021403606A1/en active Pending
- 2021-12-16 MX MX2023007244A patent/MX2023007244A/es unknown
-
2023
- 2023-06-15 CL CL2023001750A patent/CL2023001750A1/es unknown
- 2023-06-21 CO CONC2023/0008049A patent/CO2023008049A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20230121827A (ko) | 2023-08-21 |
CN116710463A (zh) | 2023-09-05 |
CA3202328A1 (en) | 2022-06-23 |
AU2021403606A1 (en) | 2023-06-22 |
MX2023007244A (es) | 2023-06-29 |
CO2023008049A2 (es) | 2023-06-30 |
JP2024502231A (ja) | 2024-01-18 |
EP4262978A1 (en) | 2023-10-25 |
IL303795A (en) | 2023-08-01 |
WO2022129283A1 (en) | 2022-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP22087539A (es) | Inhibidores de kras tricíclicos fusionados | |
MA43639B1 (fr) | Nouveaux dérivés d'ammonium, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant | |
MA45223B1 (fr) | Nouveaux dérivés de pipéridinyle subsitués par (hétéro)aryle, leur procédé de préparation et compositions pharmaceutiques les contenant | |
PE20211773A1 (es) | Moduladores de monoacilglicerol lipasa | |
MA45222B1 (fr) | Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant | |
CO2022017903A2 (es) | Compuestos de dihidroquinolinsulfonamida de ciclobutilo | |
BR112021022758A2 (pt) | Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos | |
ECSP066335A (es) | Compuestos de indazol 3,5-disustituidos, composiciones farmacéuticas y métodos para intervenir en o inhibir la proliferación celular | |
UY39264A (es) | Compuestos de dihidroquinolinsulfonamida de ciclopropilo | |
CO2022000749A2 (es) | Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos | |
CO2024001285A2 (es) | Compuestos tricíclicos como inhibidores de kras | |
BR112021021477A2 (pt) | Composto, composição farmacêutica e método para tratar uma doença mediada por jak em um indivíduo necessitando do mesmo | |
ES2038172T3 (es) | Procedimiento para preparar carboxamidas heterociclicas. | |
BR112023002957A2 (pt) | Composto, composição farmacêutica, e, métodos para tratar narcolepsia e para tratar hipersonia em um sujeito mamífero | |
UY38139A (es) | Composición antienrojecimiento y métodos para tratar el enrojecimiento cutáneo | |
BR112022016131A2 (pt) | Compostos para tratamento de infecção por coronavírus | |
CL2023002274A1 (es) | Compuestos tricíclicos y usos de los mismos | |
CL2023001750A1 (es) | Compuestos útiles para inhibir canales de sodio activados por voltaje de nav1.8 y tratar enfermedades | |
CO2021014223A2 (es) | Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de trastornos inflamatorios | |
MX9200485A (es) | Proceso para la obtencion de derivados de tetra hidro piridina y composicion farmaceutica que los contiene. | |
EA199800949A1 (ru) | Антибактериальные соединения карбапенема, содержащие их фармацевтические композиции и способы лечения | |
FR2405067A1 (fr) | Compositions pharmaceutiques contenant des derives monofonctionnels du psoralene pour le traitement des affections cutanees | |
AR035587A1 (es) | Un compuesto derivado de la triptamina y sus analogos, y una composicion farmaceutica que lo contiene | |
BR112023019496A2 (pt) | Derivados de ciclobutila 1,3-substituída e usos dos mesmos | |
BE1002236A4 (fr) | Nouveaux derives de benzylidene-cyclanones, leur procede de preparation, leur utilisation en tant qu'agents anti-oxydants et comme filtres solaires, compositions cosmetiques et pharmaceutiques les contenant. |